The FDA drug shortage list is a public database of medications the agency has determined are in short supply. It matters to GLP-1 patients because shortage status has shaped how compounded versions are prepared and how easy the commercial product has been to fill. The list changes, so check it rather than trusting a headline. TelosRX explains what it does and does not mean below.
The list is a supply tracker, not a safety rating. It tells you whether the FDA considers a medication to be in short supply right now. It does not tell you whether a compounded version is safe, and it does not tell you what you personally can access. Compounded medication is not FDA-approved either way, and any prescription is subject to medical approval by a licensed provider.
Start your intake →What the shortage list actually is
The FDA maintains a public database of drug shortages. Manufacturers are required to notify the agency when supply of certain products is interrupted or discontinued.
The agency then verifies whether demand genuinely exceeds available supply across the market. If it does, the product is listed. When supply recovers, the listing is updated and eventually removed.
Entries carry detail. The specific presentation affected, the reason given, and an estimated recovery timeline where one exists. A listing can apply to some strengths and not others.
This is a national view, not a local one. A medication can be resolved on the list and still be awkward to source at a particular pharmacy on a particular week. The reverse also happens.
Why it became a GLP-1 story
Demand for this class of medication rose faster than manufacturers could scale production. That gap produced a sustained period where supply of several presentations could not meet prescribing volume.
Patients felt it directly. Pharmacies could not fill prescriptions, doses were unavailable at the strength people had titrated to, and treatment was interrupted at exactly the point where continuity matters.
Shortage status also changed the compounding landscape. When a drug is formally listed as in shortage, there is broader latitude for pharmacies to prepare versions of it. When the shortage resolves, that latitude narrows.
That regulatory link is why the list became a topic of conversation among patients rather than just supply chain specialists. It stopped being an administrative record and started shaping access.
Key takeaway: Shortage status is about supply, not about quality. It has influenced what compounding pharmacies can prepare, but it is not a verdict on whether any given product is safe for you.
How to check the list yourself
Do not rely on a social post or an article, including this one, for current status. Listings change and articles do not.
Go to the FDA drug shortage database and search the active ingredient rather than a brand. Semaglutide and tirzepatide are the entries that matter for this class.
Read the detail rather than the headline status. Check which strengths and presentations the entry covers, and check the date the record was last updated.
Then note what the record cannot tell you. It says nothing about your pharmacy, your insurance, or your prior authorisation. Those are separate obstacles with separate fixes.
If you want to stop tracking this altogether, start an evaluation and let a provider handle sourcing.
What shortage status does not mean
A few misreadings come up constantly, and each one leads people somewhere unhelpful.
It does not mean a listed medication is unsafe. Shortage is an availability finding, not a recall and not a quality alert.
It does not mean a compounded version is FDA-approved. Compounded medication is not FDA-approved at any point in the supply cycle. Nothing on the shortage list changes that.
It does not mean the opposite either. Removal from the list does not make compounded preparation illegitimate by itself. Compounding continues to exist for patients with a documented clinical need that a commercial product cannot meet.
And it does not mean you should ration, stretch, or split your medication to make supply last. That is a dosing decision, and it belongs with your provider rather than with your anxiety.
What to do if your medication is hard to get
Interruption is the real problem behind all of this. Time off treatment tends to bring appetite back and can make restarting uncomfortable.
Tell your provider before you run out, not after. A gap you flag early can usually be managed. A gap you report three weeks later is harder to fix cleanly.
Do not source from anywhere that ships without a prescription. Sites selling research-grade peptide powder are not pharmacies, and that supply carries a different and much worse risk profile.
Do not stockpile by taking less than prescribed. Stretching doses changes your exposure in ways your provider has not planned for, and it usually produces a worse experience than a short pause would.
Ask about alternatives. A different molecule, a different format, or a different protocol may be available when your usual option is not.
How a shortage actually affects a patient
The database is abstract. The experience is not, and it tends to follow a pattern.
First comes a refill that does not arrive on time. The pharmacy says it is on order and cannot give a date. Nothing has formally gone wrong yet.
Then comes a substitution problem. Your strength is unavailable, but another one is, and someone suggests improvising with what is in stock. This is the point where people make decisions they should not be making alone.
Then comes the gap. A week becomes three. Appetite returns, the routine slips, and the restart feels harder than the original start did.
Each of those steps has a better answer if a clinician is involved early. That is the practical argument for a service with messaging built in rather than a transactional pharmacy relationship.
Questions worth asking your provider
If supply is uncertain, a short list of questions gets you further than refreshing a database.
Ask what happens if my refill is delayed. A service that has an answer ready has thought about it. One that has not will improvise on your time.
Ask whether there is an alternative molecule or format if mine becomes hard to source. Having a second option identified in advance removes most of the panic.
Ask how a gap would be handled. Restarting after a longer break often means stepping back down rather than resuming where you left off, and it helps to know that before it happens.
Ask who I contact and how fast. Unlimited messaging is only useful if someone reads it. Open an evaluation and test the response yourself.
Where TelosRX fits
TelosRX works with licensed partner compounding pharmacies and US-licensed providers. The intake is asynchronous and takes around five minutes, with review often within hours.
Compounded semaglutide is as low as $99 a month. Compounded tirzepatide is as low as $139 a month. Both ship free in two days.
If injections are the sticking point, the needle-free oral GLP-1 starts from $9 a day and dispenses oral semaglutide or oral tirzepatide at the clinician's discretion. Look at the needle-free option.
If side effects are the sticking point, microdosed tirzepatide starts as low as $116 a month. Ask about microdosing.
Plans include unlimited care-team messaging, quarterly labs, and dose adjustments. You can cancel at any time with no fee, and you pay nothing if you are declined. Plans are FSA and HSA eligible.
The wider supply picture
Shortages in general have several causes, and it is worth knowing which one you are dealing with.
Manufacturing capacity is the common driver for newer injectables. Building sterile fill and finish capacity takes years, and demand can move far faster than that.
Raw material supply is another. A single constrained input can bottleneck an otherwise healthy production line.
Quality events at a facility can halt output abruptly. Regulatory action, contamination findings, and equipment failures all show up in shortage records.
Demand shocks matter too. A sharp increase in prescribing, whether from a new indication or from public attention, can empty a supply chain that was adequate the year before.
None of these resolve quickly. That is why patients ended up living with this for an extended period rather than a few weeks.
Staying on treatment through supply noise
The practical goal is continuity. Everything else is detail.
Keep your provider informed about anything that could interrupt you. Travel, a move, a change in your pharmacy, or a delay in shipping are all worth flagging in advance.
Keep your appointments and your labs current, because a lapse in the clinical record can itself delay a refill.
Build your routine around the medication being available rather than around hoarding against the possibility that it is not. Anxiety about supply causes more dosing errors than actual shortages do.
And if you do face a gap, ask before you improvise. Message a provider and get a plan rather than guessing at one.
For the live record, see the FDA drug shortages resource. For how compounding is regulated, see the FDA compounding questions and answers.
Frequently Asked Questions
What is the FDA drug shortage list?
It is a public database where the FDA records medications it has determined are in short supply nationally. Manufacturers must report supply interruptions, and the agency verifies whether demand exceeds supply. Entries include the affected presentations, the stated reason, and the date the record was last updated.
Are GLP-1 medications currently in shortage?
Status changes over time, so check the live FDA record rather than relying on any article. Search the active ingredient, such as semaglutide or tirzepatide, and read which strengths the entry covers. A national listing also may not match what your local pharmacy can fill.
Does shortage status make compounded medication legal?
Shortage status has influenced how broadly pharmacies may prepare versions of a listed drug, but compounding does not exist only because of shortages. It exists to meet documented clinical needs for individual patients. Compounded medication is not FDA-approved regardless of what the shortage list says.
What should I do if my pharmacy cannot fill my prescription?
Tell your provider before you run out rather than after. They can look at alternatives, including a different molecule, a different format, or an adjusted protocol. Do not stretch, split, or skip doses to make supply last, because that is a clinical decision.
Is it safe to buy GLP-1 medication online during a shortage?
Only through a licensed pharmacy with a real prescription behind it. Sites that ship without a clinician reviewing you, or that sell research-grade powder, are not pharmacies. Look for state licensure, a named prescriber licensed where you live, and LegitScript certification.
Can TelosRX help if I have been interrupted?
Yes. Start the asynchronous intake and tell the provider what you were taking, at what dose, and how long the gap has been. After a longer break many providers prefer to restart lower and build back up. Any plan is subject to medical approval by a licensed provider.
TelosRX is LegitScript-certified. Compounded medication is not FDA-approved and is prepared under federal compounding regulations. This article is general information, not medical advice, and does not replace guidance from your own provider. Approval is subject to evaluation by a licensed provider, and approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Worried about a gap in supply? Message the TelosRX care team or start your evaluation at TelosRX.